Messina Mark, Nechuta Sarah
Soy Nutrition Institute Global, Jefferson, MO, USA.
Grand Valley State University, Allendale, MI, USA.
Curr Nutr Rep. 2025 Mar 25;14(1):50. doi: 10.1007/s13668-025-00640-5.
This narrative review aims to determine the impact of postdiagnosis isoflavone intake, via supplements and foods, on breast cancer outcomes. Foods derived from soybeans are uniquely rich sources of isoflavones, naturally occurring compounds that can bind to estrogen receptors although the extent to which they exert estrogen-like effects in humans is unclear. Isoflavones have been rigorously investigated for a wide range of health benefits including breast cancer prevention. However, their classification as phytoestrogens has led to concern that isoflavones and hence, soy food consumption, could worsen the prognosis of women with breast cancer and interfere with the efficacy of endocrine therapy for this disease.
Research in athymic ovariectomized mice shows isoflavones stimulate the growth of existing estrogen-sensitive mammary tumors. However, extensive clinical research indicates that neither soy foods nor isolated isoflavones affect markers of breast cancer risk including mammographic density and breast cell proliferation. No effects are observed even when isoflavone exposure greatly exceeds typical intake in Asian countries. Furthermore, the results from epidemiologic studies indicate postdiagnosis isoflavone intake from soy foods reduces recurrence and possibly mortality from breast cancer. Additionally, the limited observational data do not show that isoflavones interfere with the efficacy of tamoxifen or aromatase inhibitors. Regardless of their treatment status, evidence indicates that women with breast cancer can safely consume soy foods. Limiting intake to no more than two servings of traditional Asian soy foods daily, an amount that provides approximately 50 mg isoflavones, is recommended, not because data indicate exceeding this amount is harmful, but because few population-based studies involved participants consuming more than this intake recommendation.
本叙述性综述旨在确定诊断后通过补充剂和食物摄入异黄酮对乳腺癌预后的影响。大豆制品是异黄酮的独特丰富来源,异黄酮是天然存在的化合物,可与雌激素受体结合,但其在人体内发挥类似雌激素作用的程度尚不清楚。异黄酮已被广泛研究其对包括预防乳腺癌在内的多种健康益处。然而,它们被归类为植物雌激素引发了人们的担忧,即异黄酮以及因此食用大豆食品可能会恶化乳腺癌患者的预后,并干扰该疾病内分泌治疗的疗效。
对无胸腺卵巢切除小鼠的研究表明,异黄酮会刺激现有的雌激素敏感乳腺肿瘤生长。然而,大量临床研究表明,大豆食品和分离出的异黄酮均不会影响乳腺癌风险标志物,包括乳腺X线密度和乳腺细胞增殖。即使异黄酮暴露量大大超过亚洲国家的典型摄入量,也未观察到任何影响。此外,流行病学研究结果表明,诊断后从大豆食品中摄入异黄酮可降低乳腺癌的复发率,并可能降低死亡率。此外,有限的观察数据并未表明异黄酮会干扰他莫昔芬或芳香化酶抑制剂的疗效。无论其治疗状态如何,有证据表明乳腺癌患者可以安全地食用大豆食品。建议每天摄入不超过两份传统亚洲大豆食品,该量可提供约50毫克异黄酮,并非因为数据表明超过此量有害,而是因为很少有基于人群的研究涉及摄入量超过此建议的参与者。